Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epeius’s osteosarcoma drug wins orphan drug designation
The FDA granted the orphan drug status based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the
The FDA granted the orphan drug status based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the
Over the next several weeks, TomoTherapy and Hi-Art will negotiate a definitive purchase agreement. The transaction is expected to close in the fourth quarter of 2008, at which
The Phase I study succeeded in meeting both its primary and secondary objectives. The primary objectives were to evaluate the safety and tolerability and to assess the pharmacokinetics
Tim Clover, CEO of t+ Medical Holdings, and Andrew Hall, founder and managing director of Vivatec, in a joint statement said: “This acquisition enables t+ Medical to expand
The study by the Merck Serono division will assess the clinical benefit of the targeted cancer therapy Erbitux (cetuximab) in combination with cisplatin and capecitabine as a first-line
The culture media covered by this patent contain the key combination of two or three types of enzyme inhibitor. Professor Smith discovered that by inhibiting certain key enzymes
The facility, built as a result of a co-operative agreement between the company and the University Business Park, is an advanced construction, linked to Ark’s existing manufacturing and
Under the terms of the license agreement with Cancer Research Technology (CRT), ValiRx has a period of 12 months in which to complete the pre-clinical regulatory development of
The existing Canadian Pennsaid Plus license between Nuvo and Squire has been amended to grant Squire the right to market, distribute and sell Pennsaid Plus in South Africa
Under the terms of the agreement, Artes Medical will receive exclusive distribution and marketing rights for Elevess in the US. Elevess is an injectable filler that reduces the